Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
Abstract
Aims: The fibrosis-4 (FIB-4) score is used to identify risk of advanced liver fibrosis. This post hoc analysis investigated its prognostic value for cardiovascular (CV) outcomes and its relevance to the effects of dapagliflozin.
Materials and methods: DECLARE-TIMI 58 was a randomised, placebo-controlled phase 3 trial investigating dapagliflozin in patients with type 2 diabetes (T2D) and either atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk. Participants were stratified by baseline FIB-4 scores (< 1.30, 1.30 to < 2.67, and ≥ 2.67). Hazard ratios (HRs) and 95% confidence intervals (CIs) for dapagliflozin versus placebo were calculated for the two primary outcomes (major adverse cardiovascular events [MACE] and the composite of CV death and hospitalisation for heart failure [HHF]).
Results: Of 17 160 patients enrolled, 16 361 were included (median follow-up of 4.2 years). Distribution across FIB-4 categories was: < 1.30, n = 9084 (55.5%); 1.30 to < 2.67, n = 6556 (40.7%); and ≥ 2.67, n = 621 (3.8%), with similar ASCVD prevalence across groups (40%-43%). In the placebo arm, the ≥ 2.67 FIB-4 group had the highest event rates for MACE, HHF, CV death, and all-cause death. MACE HRs (95% CIs) for dapagliflozin versus placebo were 0.95 (0.83-1.10), 0.92 (0.79-1.08), and 0.61 (0.38-0.97) across ascending FIB-4 groups. For the CV death and HHF composite endpoint, they were 0.81 (0.67-0.98), 0.90 (0.73-1.10), and 0.50 (0.28-0.90). Dapagliflozin reduced aspartate…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 9,084 participants or records.
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.